Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?

ResMed (RMD), a medical products manufacturer for respiratory disorders, has consistently surpassed earnings estimates, averaging a 3.04% beat over the past two quarters. The company currently holds a positive Zacks Earnings ESP of +5.16% and a Zacks Rank #3 (Hold), a combination that historically indicates a high probability (nearly 70%) of another earnings surprise. This suggests ResMed is well-positioned for an earnings beat in its next report, anticipated on July 31, 2025.

Analysis

ResMed (RMD), a medical products manufacturer for respiratory disorders, has demonstrated a consistent ability to outperform earnings expectations, surpassing consensus estimates by an average of 3.04% over the last two quarters. This performance includes a significant 5.65% beat in the penultimate quarter ($2.43 actual vs. $2.30 estimate) and a 0.42% surprise in the most recent quarter. Forward-looking indicators for its upcoming report on July 31, 2025, appear favorable. The company currently has a positive Zacks Earnings ESP (Expected Surprise Prediction) of +5.16%, which indicates that the most recent analyst forecasts are more bullish than the broader consensus. This positive ESP, when combined with RMD's Zacks Rank #3 (Hold), creates a statistical scenario that has historically resulted in an earnings beat nearly 70% of the time, suggesting a high probability that the company's positive earnings streak may continue.

Key Decisions for Investors

• Given the positive +5.16% Earnings ESP and the high historical probability of an earnings beat, investors may consider RMD a candidate for a tactical long position ahead of its July 31, 2025, report.
• The stock's Zacks Rank #3 (Hold) suggests it may be trading at a fair valuation, warranting a risk assessment that balances the potential for a short-term catalyst from an earnings beat against a neutral medium-term outlook.
• Investors should monitor for any changes in the Earnings ESP metric leading up to the report, as downward revisions could weaken the case for an earnings surprise and signal a shift in analyst sentiment.